Experts discussed the benefits of Home Monitoring technology from the perspective of patients, hospitals and payers for the first time at a press conference held by BIOTRONIK at the European Society of Cardiology's annual congress, ESC Congress 2014.

A next-generation biodegradable drug-eluting stent proved noninferior to the standard of care in a randomized clinical trial that imposed minimal exclusion criteria, according to results published online Sept. 1 in The Lancet and simultaneously presented at the European Society of Cardiology meeting in Barcelona.

Given its etiologic role in atherogenesis, the management of risk related to low-density lipoprotein (LDL) has become a vital part of treating patients in danger of atherosclerotic cardiovascular disease (ASCVD). 

The Centers for Medicare & Medicaid Services (CMS) will kick off its second round of Medicare penalties for 30-day readmissions soon, this time with CABG in its crosshairs.

PCI guided by fractional flow reserve (FFR) in patients with stable coronary artery disease who were treated with second-generation drug-eluting stents and medical therapy reduced the need for urgent revascularization compared with medical therapy alone, according to two-year results from FAME 2.

Patients undergoing cardiac surgery had mixed results when using colchicine to reduce the incidence of postpericardiotomy syndrome, postoperative atrial fibrillation or postoperative pericardial or plural effusion, according to a study published online Aug. 30 in JAMA.

A novel drug that combines an ARB with a neprilysin inhibitor proved superior to the ACE inhibitor enalapril, even when the latter was prescribed at its target dose, for reducing the risk of death and hospitalization for heart failure in patients with reduced ejection fraction.

It is no secret that peripheral artery disease (PAD) is a multidimensional disease affecting 8 to 12 million Americans—yet only 2 million even know they have it.